We get very few complaints from the public. We get some complaints from provincial drug plans, but mostly the reason we're having these hearings and more investigations is that there's a tendency toward non-compliance with our guidelines. We believe the reason is there are fewer blockbuster drugs. A blockbuster drug would be one of a kind that would cure a particular disease and it would command a premium and the drug company would be very happy to get that. Rather, what we're seeing now--to use the colloquial expression--is tweaking of already existing medications. They change the number of times a day that you take it--instead of the same chemical three times a day, they wrap it up in a coating and you take it once a day, and the drug companies want quite a high premium for that.
On March 28th, 2007. See this statement in context.